
Akebia Therapeutics Inc (NASDAQ:AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical.
As a result of the termination of the agreements, Akebia will regain the rights for Vadadustat in the United States, Europe, China, Russia, Canada, Australia, and the Middle East. Otsuka will pay Akebia a $55 million settlement fee.